Differential Expression of Steroid 5α-Reductase Isozymes and Association with Disease Severity and Angiogenic Genes Predict Their Biological Role in Prostate Cancer

    June 2010 in “ Endocrine Related Cancer ”
    Kakoli Das, Philip Cedrick Lacsamana Lorena, Lai Kuan Ng, Diana Lim, Liang Shen, Woei Yun Siow, Ming Ming Teh, Juergen Reichardt, Manuel Salto–Tellez
    TLDR SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.
    The study examined the roles of steroid 5α-reductase isozymes, SRD5A1 and SRD5A2, in prostate cancer (PC) using samples from 62 patients. It found that SRD5A1 was associated with more advanced cancer stages and higher Gleason scores, while SRD5A2 correlated with VEGF expression. Dutasteride, which inhibits both isozymes, was more effective in reducing tumor cell viability than finasteride, which only inhibits SRD5A2. Despite treatment, angiogenic genes remained active, indicating potential resistance. The study highlighted SRD5A1's predominance in advanced PC and suggested further exploration of these isozymes as therapeutic targets.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results

    Related Community Posts Join

    6 / 817 results

      community DHT and 5AR respect post, it's importance within the brain

      in Research/Science  111 upvotes 2 years ago
      The conversation discusses whether to use finasteride for hair loss, considering its role in inhibiting DHT and 5AR, which can affect brain function and mood. Some users report anxiety and depression from finasteride, while others do not experience these side effects and emphasize the importance of DHT for brain and prostate health.

      community Why does it seem everyone favors finasteride over dutasteride?

      in Female  62 upvotes 1 year ago
      The conversation discusses preferences for hair loss treatments, specifically finasteride over dutasteride. Users share personal experiences, cost considerations, FDA approval status, and potential side effects, with some switching between treatments to find what works best for them.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 1 year ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

    Related Research

    2 / 2 results